Imprinted genes have important roles in normal development and disease, particularly in the control of fetal growth, placenta development, and behaviour after birth. We are particularly interested in the local and regional regulation of one of the most prominent imprinting clusters on chromosome 11 p15.5 in human and chromosome distal 7 in mouse. In the mouse we have completely cloned and characterised the cluster which contains at least 8 imprinted genes with dramatic effects on fetal growth and cell proliferation. In the human the cluster is associated with the fetal overgrowth and cancer syndrome, Beckwith-Wiedemann syndrome. In this syndrome, the otherwise imprinted Insulin like growth factor 2 gene (IGF2) is frequently biallelically expressed. We have demonstrated that transgenic overexpression of IGFZ leads to many of the symptoms of BWS. The control of IGFZ imprinting and expression is therefore crucial. We have now made new mutations, one by Cre loxP mediated knockout and one by radiation mutagenesis, that affect IGFZ imprinting and expression. The radiation induced mutation results in methylation of H19, a neighbouring imprinted gene which is involved in the control of IGF2 imprinting. The Cre loxP knockout deletes a placental specific control region and results in a specific form of intrauterine growth retardation. Processes of masculinisation and defeminisation are thought to be involved in the sex differentiation of mammalian reproductive behaviour. The CYP 19 P450 aromatase, converting androgen to oestrogen, is a key enzyme in the development of neural systems, and the activity of this enzyme is likely to be one of the factors determining brain sex differentiation. We have examined the localisation and regulation of the brain aromatase using the mouse as a model. In primary cell cultures of embryonic mouse hypothalamus there are sex differences in aromatase activity during early and late embryogenesis, with a higher capacity for oestrogen formation in the male than the female. Using a specific antibody to the mouse aromatase, immunoreactivity is restricted to neuronal soma and neurites in hypothalamic cultures. There are more neurones containing expressed aromatase in the male hypothalamus than in the female. Therefore, gender-specific differences in embryonic ammatase activity are neuronal. Testosterone both increases foetal aromatase activity specifically in hypothalamic neurones and aromatase mRNA. Androgen also increases the numbers of aromatase-immunoreactive neumnes in the hypothalamus.
Endogenous inhibitors, notably Sa-reduced androstanediones and neurosteroids formed in the brain represent an enzymatic control system involved in fine regulation of the aromatase. Our work suggests that the embryonic male hypothalamus and other androgen target areas contain a network of neurones which has the capacity to provide oestrogen for the sexual differentiation of brain mechanisms of behaviour during critical phases of development.
The enzyme forming oestrogen, aromatase, is regulated both genomically and by metabolic inhibition involving brain steroids.
PERINATAL HORMONE LEVELS AND THEIR ROLE IN

B5 GLUCOCORTICOIDS AND FETAL PROGRAMMING NORMAUABNORMAL DEVELOPMENT AND FUNCTION OF THE MALE REPRODUCTIVE SYSTEM
Jonathan R. Seckl, Moffat J. Nyirenda and Brian R. Walker.
General Hospital, Edinburgh EH4 2XU, U.K. Substantial epidemiological evidence associates low weight at birth with an increased risk of adult cardiovascular and metabolic disorders. The underlying mechanisms are unknown. In rats, fetal exposure to excess glucocorticoids (GCs), notably in the last trimester, retards prenatal growth and 'programmes' permanent adult hypertension and hyperglycaemia. Normally however, 1 19-hydroxysteroid dehydrogenase type in the placenta and fetal tissues protects from excess maternal GCs by catalysing rapid inactivation of cortisol and corticosterone to inert I I-keto products. In rats and humans there is considerable variation in placental 1 IS-HSD2 activity near term, and enzyme activity correlates with birth weight. In the pregnant rat, inhibition of feto-placental 1 15-HSD2 also reduces birth weight and produces permanently hypertensive and hyperglycaemic adult offspring. The possible mechanisms of such early life programming by GCs have been addressed in rats and include (i) programming of vasoconstrictor responses, (ii) alteration of the 'set point' of the hypothalamic-pituitary-adrenal (HPA) axis and (iii) programming of increased hepatic PEPCK gene expression. HPA axis programming also occurs in humans; birthweight correlates inversely with blood cortisol levels in middle age. The glucocorticoid receptor gene itself may be a key target for prenatal glucocorticoid programming, at least in brain (hippocampus) and liver. Fetal GC excess, perhaps due to 119-HSD2 deficiency, may, in part, explain the links between early life events and subsequent disease. 
